Efficacy and safety of "BioBoost" supplement on the incidence of COVID-19 symptoms of asymptomatic family members of COVID-19 patients

Efficacy and safety of "BioBoost" supplement on the incidence of COVID-19 symptoms of asymptomatic family members of COVID-19 patients: A Randomized cluster clinical trial, parallel, Phase 3, doubled blinded and placebo controlled

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200318046812N3

Enrollment

500

Registered

2021-01-12

Start date

2020-12-20

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: ''Intervention group:'' In this group, probiotics are given to the patients' families. Biomus supplement consists of 12 essential vitamins and minerals along with probiotics (a mixture

Eligibility

Sex/Gender

All

Age

18 Years to 63 Years

Inclusion criteria

Inclusion criteria: Confirmation of infection by PCR in a family member Informed written consent Living in Tehran Number of family members between 2 and 5 Age between 18 to 63 years No prognostic signs of Covid-19 disease two weeks before enrollment

Exclusion criteria

Exclusion criteria: Not participating in another clinical trial in the last three months Do not use other supplements (containing vitamins, minerals, and probiotics) No documented history of Covid-19 infection in healthy family members Pregnancy / breastfeeding Drug sensitivity to the compounds in the intervention Temporary residence or immigration and consecutive relocation from Tehran Use similar supplements

Design outcomes

Primary

Measure	Time frame
?S?everity of cough. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone followup.;?Severity of shortness of breath. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone followup.	—

Secondary

Measure	Time frame
Preentation of fever, headache, .. as a Yes/ no. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.;Recording the severity of symptoms by comparing Likert from a score of 1 to 10. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.;The duration of symptoms and duration of hospitalization based on the date of onset and date of remission. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.	—

Measure

Time frame

Preentation of fever, headache, .. as a Yes/ no. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.;Recording the severity of symptoms by comparing Likert from a score of 1 to 10. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.;The duration of symptoms and duration of hospitalization based on the date of onset and date of remission. Timepoint: The variable in the drug and placebo groups can be recorded at the end of the first, second and fourth weeks. Method of measurement: Telephone follow-up.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Saadat

Bagheiat-allah University of Medical Sciences

mghaneister@gmail.com+98 21 8860 0067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026